The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
A 20-year-old experiencing hair loss since age 16 is using finasteride and minoxidil and is considering future hair transplants. Discussions include the potential for multiple transplants, the use of body hair for coverage, and the importance of treatments like dutasteride and scalp micropigmentation for maintaining hair density.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfolliclestemcells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Hair loss discussion with a focus on a single resilient hair, jokingly called "chad hair," that remains despite hairline receding. Some users suggest microneedling and hairfollicle cloning as potential treatments.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
Dr. Tsuji's stemcellhair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
A user with long-term hair loss has been using topical minoxidil, finasteride, RU58841, ketoconazole, and dermastamping for 8 months. They are unsure if the new hairs are miniaturized or vellus.
Finasteride, minoxidil, dermarolling, and topical antiandrogens are effective for hair regrowth. Future treatments may include CB0301 and hair cloning.
PP405 is a potential hair loss treatment that may reactivate dormant hairfollicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hairfollicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hairfollicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.
User experiences slow hair regrowth despite using finasteride, topical minoxidil, and supplements like biotin, zinc, and collagen. They seek advice on addressing overall slow hair regrowth.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hairfollicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfolliclestemcells and may maintain gains without immediate loss, unlike minoxidil.
A user shared their experience with hair loss treatments, including topical minoxidil, finasteride, RU58841, and microneedling, noting significant hair regrowth except at the hairline. They plan to start oral minoxidil and switch to a combination treatment, while another user mentioned that some miniaturized hairs may not fully recover.
MCL-1 protein may help maintain hairfollicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stemcell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.
The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.
The user stabilized hair loss with oral finasteride, dutasteride, and topical minoxidil, and underwent a stemcell and PRP procedure. Recent increased hair shedding may be due to restarting dermarolling, affecting minoxidil absorption, or the waning effects of the stemcell treatment.
The user discusses their experience with hair loss despite taking estrogen and cyproterone, and estimates needing around 3000 grafts for a feminine hairline. They are considering getting the procedure done in Turkey due to high European costs.